Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Immunotherapy of hepatocellular carcinoma with small double-stranded RNA

Authors: Tatyana O Kabilova, Larisa V Kovtonyuk, Evgeniy V Zonov, Elena I Ryabchikova, Nelly A Popova, Valeriy P Nikolin, Vasiliy I Kaledin, Marina A Zenkova, Valentin V Vlassov, Elena L Chernolovskaya

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited therapeutic options. Since HCC has been shown to be immunogenic, immunotherapy is considered a promising therapeutic approach. Small interfering RNAs (siRNAs), depending on their structure and sequence, can trigger the innate immune system, which can potentially enhance the adaptive anticancer immune response in the tumor-bearing subjects. Immunostimulatory properties of nucleic acids can be applied to develop adjuvants for HCC treatment.

Methods

The transplantable HCC G-29 tumor in male CBA/LacSto (CBA) mice was used to study the effects of immunostimulatory RNA on tumor growth. Tumor size, metastases area in different organs of mice and mouse survival rate were analyzed. Furthermore the mouse serum IFN-α levels were measured using ELISA.

Results

In the present study, we found that a 19-bp RNA duplex (ImmunoStimulattory RNA or isRNA) with 3-nt overhangs at the 3′-ends of specific sequence displays immunostimulatory, antitumor, and antimetastatic activities in mice bearing HCC G-29. Our results demonstrate that isRNA strongly increases the level of interferon-α (IFN-α) by up to 25-fold relative to the level in mice injected with Lipofectamine alone (Mock), and to a lesser extent increases the level of proinflammatory cytokine interleukin-6 (IL-6) (by up to 5.5-fold relative to the Mock level), in mice blood serum. We showed that isRNA reliably (P < 0.05) inhibits primary tumor growth in mice compared to the mock group. Furthermore, injections of isRNA significantly enhanced necrotic processes in the center of the primary tumor, and decreased by twofold the width of the undifferentiated peripheral zone and the number of mitotic cells in this zone. The results showed that isRNA efficiently reduces the area of metastases in the liver, kidneys, and heart of CBA/LacSto mice with HCC.

Conclusions

The obtained results clearly demonstrate immunostimulatory and antimetastatic properties of the isRNAs in mice with HCC. Consequently, this short double-stranded RNA can be considered as a potential adjuvant for the therapy of HCC.
Appendix
Available only for authorised users
Literature
1.
Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009, 27: 80-92.PubMed
2.
Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S: Surgery for small liver cancers. Semin Surg Oncol. 1993, 9: 298-304. 10.1002/ssu.2980090404.CrossRefPubMed
3.
Livragh T, Lazzaroni S, Pellicano S, Ravasi S, Torzilli G, Vettori C: Percutaneous ethanol injection of hepatic tumours: single-session therapy with general anesthesia. AJR Am J Roentgenol. 1993, 161: 1065-1069. 10.2214/ajr.161.5.8273612.CrossRef
4.
Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE: Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999, 353: 1676-1677. 10.1016/S0140-6736(99)00368-2.CrossRefPubMed
5.
Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 2000, 32: 1224-1229. 10.1053/jhep.2000.20456.CrossRefPubMed
6.
7.
Gold JE, Masters TR, Osband ME: Autolymphocyte therapy III effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes. J Surg Res. 1995, 59: 279-286. 10.1006/jsre.1995.1165.CrossRefPubMed
8.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363: 411-422. 10.1056/NEJMoa1001294.CrossRefPubMed
9.
Waldmann TA: Immunotherapy: past, present and future. Nat Med. 2003, 9: 269-277. 10.1038/nm0303-269.CrossRefPubMed
10.
Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ: Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006, 45: 246-253. 10.1016/j.jhep.2005.12.027.CrossRefPubMed
11.
Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W: Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014, 134: 342-351. 10.1002/ijc.28372.CrossRefPubMed
12.
Ishikawa T: Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008, 14: 6140-6144. 10.3748/wjg.14.6140.CrossRefPubMedPubMedCentral
13.
14.
Ishikawa T, Ichida T: Features of hepatitis B virus-related hepatocellular carcinoma. Nihon Rinsho. 2001, 59: 435-439.PubMed
15.
Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995, 346: 1051-1055. 10.1016/S0140-6736(95)91739-X.CrossRefPubMed
16.
Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001, 357: 196-197. 10.1016/S0140-6736(00)03595-9.CrossRefPubMed
17.
Olejniczak M, Galka-Marciniak P, Polak K, Fligier A, Krzyzosiak WJ: RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents. RNA. 2012, 18: 930-935. 10.1261/rna.025627.110.CrossRefPubMedPubMedCentral
18.
Desmet CJ, Ishii KJ: Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol. 2012, 12: 479-491. 10.1038/nri3247.CrossRefPubMed
19.
El-Omar EM, Ng MT, Hold GL: Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene. 2008, 27: 244-252. 10.1038/sj.onc.1210912.CrossRefPubMed
20.
McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-himes JA, Efler SM, Davis HL: Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007, 46: 1341-1349. 10.1002/hep.21773.CrossRefPubMed
21.
Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005, 42: 724-731. 10.1002/hep.20839.CrossRefPubMed
22.
Xiang AX, Webber SE, Kerr BM, Rueden EJ, Lennox JR, Haley GJ, Wang T, Ng JS, Herbert MR, Clark DL, Banh VN, Li W, Fletcher SP, Steffy KR, Bartkowski DM, Kirovsky LI, Bauman LA, Averett DR: Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007, 26: 635-640. 10.1080/15257770701490472.CrossRefPubMed
23.
Pappas SC: Good science behind hepatitis C virus antiviral drug development: necessary but not sufficient. Hepatology. 2010, 51: 1897-1903. 10.1002/hep.23531.CrossRefPubMed
24.
Kabilova TO, Vladimirova AV, Zenkova MA, Chernolovskaya EL, Vlassov VV: Antiproliferative and interferon-inducing activities of unique short double-stranded RNA. Dokl Biochem Biophys. 2011, 436: 8-11. 10.1134/S1607672911010042.CrossRefPubMed
25.
Kabilova TO, Meschaninova MI, Venyaminova AG, Nikolin VP, Zenkova MA, Vlassov VV, Chernolovskaya EL: Short double-stranded RNA with immunostimulatory activity: sequence dependence. Nucleic Acid Ther. 2012, 22: 196-204.PubMed
26.
Judge AD, Sood V, Shaw JR, Fang D, McClintock K, Maclachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005, 23: 457-462. 10.1038/nbt1081.CrossRefPubMed
27.
Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol. 2008, 180: 1535-1544. 10.4049/jimmunol.180.3.1535.CrossRefPubMed
28.
Kaledin VI, Zhukova NA, Nikolin VP, Popova NA, Beliaev MD, Baginskaya NV, Litvinova EA, Tolstikova TG, Lushnikova EL, Semenov DE: Hepatocarcinoma-29, a metastasizing transplantable mouse tumor inducing cachexia. Bull Exp Biol Med. 2009, 148: 903-908. 10.1007/s10517-010-0848-9.CrossRefPubMed
29.
Wang H, Chen L: Tumor microenviroment and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol. 2013, 28: 43-48.CrossRefPubMed
30.
Seki S, Nakashima H, Nakashima M, Kinoshita M: Antitumor immunity produced by the Liver Kupffer Cells, NK Cells, NKT Cells, and CD8+ CD122+ TCells. Clin Dev Immunol. 2011, 2011: 868345-CrossRefPubMedPubMedCentral
31.
Wang YC, Xu GL, Jia WD, Han SJ, Ren WH, Wang W, Liu WB, Zhang CH, Chen H: Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation. 2012, 35: 143-149. 10.1007/s10753-011-9299-3.CrossRefPubMed
32.
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, De FA, Endres S, Hartmann G: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005, 11: 263-270. 10.1038/nm1191.CrossRefPubMed
33.
Shin D, Kim SI, Park M, Kim M: Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem Biophys Res Commun. 2007, 364: 436-442. 10.1016/j.bbrc.2007.10.012.CrossRefPubMed
34.
Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Hacker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tuting T, et al: 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008, 14: 1256-1263. 10.1038/nm.1887.CrossRefPubMed
35.
Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA: siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol. 2012, 90: 187-196. 10.1038/icb.2011.19.CrossRefPubMed
36.
37.
Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009, 27: 925-932. 10.1038/nbt.1564.CrossRefPubMedPubMedCentral
38.
Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, Pal S, Bhatia R, Raubitschek A, Yu H, Kortylewski M: TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013, 121: 1304-1315. 10.1182/blood-2012-07-442590.CrossRefPubMedPubMedCentral
39.
40.
Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB: mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A. 2002, 99: 637-642. 10.1073/pnas.022637199.CrossRefPubMedPubMedCentral
41.
Karikó K, Bhuyan P, Capodici J, Ni H, Lubinski J, Friedman H, Weissman D: Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs. 2004, 177: 132-138. 10.1159/000079987.CrossRefPubMed
42.
Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, Karpilow J, Marshall WS, Khvorova A: Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA. 2006, 12: 988-993. 10.1261/rna.2340906.CrossRefPubMedPubMedCentral
43.
Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA: Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 2006, 34: 4900-4911. 10.1093/nar/gkl464.CrossRefPubMedPubMedCentral
44.
Zhang Z, Weinschenk T, Guo K, Schluesener HJ: siRNA binding proteins of microglial cells: PKR is an unanticipated ligand. J Cell Biochem. 2006, 97: 1217-1229. 10.1002/jcb.20716.CrossRefPubMed
45.
Yang C, Li L, Xue Y, Zhao Z, Zhao T, Jia Y, Rong R, Xu M, Nicholson ML, Zhu T, Yang B: Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA. J Transl Med. 2013, 11: 210-10.1186/1479-5876-11-210.CrossRefPubMedPubMedCentral
46.
Meng Z, Zhang X, Wu J, Pei R, Xu Y, Yang D, Roggendorf M, Lu M: RNAi induces innate immunity through multiple cellular signaling pathways. PLoS One. 2013, 8: e64708-10.1371/journal.pone.0064708.CrossRefPubMedPubMedCentral
47.
Hafner M, Zawatzky R, Hirtreiter C, Buurman WA, Echtenacher B, Hehlgans T, Mannel DN: Antimetastatic effect of CpG DNA Mediated by Type I IFN. Cancer Res. 2001, 61: 5523-5528.PubMed
Metadata
Title
Immunotherapy of hepatocellular carcinoma with small double-stranded RNA
Authors
Tatyana O Kabilova
Larisa V Kovtonyuk
Evgeniy V Zonov
Elena I Ryabchikova
Nelly A Popova
Valeriy P Nikolin
Vasiliy I Kaledin
Marina A Zenkova
Valentin V Vlassov
Elena L Chernolovskaya
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-338

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Erratum

Erratum To: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines

Research article

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy

Research article

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome

Research article

Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline

Research article

FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling

Research article

Nasopharyngeal carcinoma with paranasal sinus invasion: the prognostic significance and the evidence-based study basis of its T-staging category according to the AJCC staging system
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits